Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kenalog for Persistent Choroidal Effusions Post Glaucoma Surgery
NCT02917564Phase 4Unknown
- Sponsor
- Sunnybrook Health Sciences Centre
- Start
- Oct 2020
- Primary completion
- May 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of triamcinolone in choroidal effusion (CD) (2 arms), sponsored by Sunnybrook Health Sciences Centre. Primary endpoint: Time to resolution of choroidal effusion at 3 months. Status: unknown.
02
Drugs
triamcinolone
03
Conditions
choroidal effusion (CD)
Beyond the preview
Go deeper on NCT02917564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02917564.